Connect your AI

Sutro Biopharma STRO Total Equity

Total Equity at other companies

PfizerPFE

$90.1B-0.3%

Gilead SciencesGILD

$23.52B+22.7%

RegenxbioRGNX

$21.08M-92.3%

Nuvectis Pharma, Inc.NVCT

$14.22M-32.1%

XencorXNCR

$515.63M-19.4%

AnaptysBio, Inc.ANAB

$12.75M-62.5%

Other financials

Income statement

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total assets$242.0M-24.7%

Cash flow

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sutro Biopharma's total equity?: Sutro Biopharma (STRO) reported total equity of -$66.89M in Q1 2026.
How has Sutro Biopharma's total equity changed year-over-year?: Sutro Biopharma's total equity decreased by 159.1% year-over-year, from -$25.81M to -$66.89M.
What is the long-term trend for Sutro Biopharma's total equity?: Over 5 years (2020 to 2025), Sutro Biopharma's total equity has grown at a -16.8% compound annual growth rate (CAGR), from $332.05M to -$132.45M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.